- Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysisWang, Ting; Cai, Liyu; Guo, Zefeng; You, Peimeng; Liu, Shengbo; Qiu, Hongrui; Li, Hao; Wu, Shaowei; Zhou, HaiyuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III studyHuang, J.; Song, Y.; Kou, X.; Tan, Z.; Zhang, S.; Sun, M.; Zhou, J.; Fan, M.; Zhang, M.; Song, Y.; Li, S.; Yuan, Y.; Zhuang, W.; Zhang, J.; Zhang, L.; Jiang, H.; Gu, K.; Ye, H.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
- Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinomaLiu, Jianhua; Zhang, Jia-Tao; Zhu, Changbin; Li, Weiwei; Li, Qian; Huang, Zhan; Qiao, Guibin; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
期刊论文
Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma
1被引23阅读
